Symbiotix Biotherapies, Inc. is a pioneering immunomodulation company headquartered in Boston, Massachusetts that is developing Reglemers™, a novel class of molecular therapeutics derived from the human microbiome that modulate regulatory T cells. Our company’s Scientific Founders are several of the world’s leading researchers in this field, and we are commercializing technology that has been developed over many years at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College. We are moving forward a capital-efficient R&D model that leverages the capabilities of contract research organization, academic laboratories and partner organizations.